Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
Abstract
Current guidelines for managing heart failure with preserved ejection fraction (HFpEF) focus on controlling volume overload as needed and adding an SGLT-2 inhibitor. Because SGLT-2 inhibitors are thought to have a class effect in treating HFpEF, there is no consensus on a preferred agent, and existing studies often yield conflicting results. In this study, we aimed to compare dapagliflozin (DAP, 10mg once daily) and empagliflozin (EMP, 10mg once daily) for the management of HFpEF.
We conducted a retrospective cohort analysis of deidentified, aggregate patient data from the TriNetX research network. Patients aged ≥18 years with a diagnosis of HFpEF (ICD-10 codes: I50.3x or I50.4x with an LVEF >=50%) between January 2018 and January 2022 were identified. Patients were then divided into two groups based on whether they received DAP or EMP. Following a tight 1:1 propensity score matching for baseline demographics, prescribed medications, comorbidities, LVEF, baseline HgbA1c and NT-proBNP/BNP levels we calculated odds ratios and Cox proportional hazards ratios to compare outcomes over a two-year follow-up period. Primary outcomes included all-cause mortality and acute decompensated HF (defined by ICD codes or need for IV diuretics). Secondary outcomes included HgbA1c change and incidence of UTI or diabetic ketoacidosis (DKA).
The matched cohort included 10,672 patients with HFpEF (5,336 per group; mean age 70.4 years; 53.4% female; 69% White; mean LVEF 61.8%). All-cause mortality…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 10,672 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.